bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company headquartered in San Antonio, Texas, focused on developing non-invasive diagnostic tests and targeted cancer therapeutics. The company's core mission is to address the urgent need for early-stage cancer diagnosis and treatment, aiming to improve patient outcomes through accurate detection and advanced therapies.

The company's primary product is CyPath® Lung, a non-invasive diagnostic test designed for the early detection of lung cancer. This test utilizes advanced flow cytometry and proprietary artificial intelligence (AI) to analyze cell populations in sputum samples, identifying characteristics indicative of malignancy. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) through Precision Pathology Laboratory Services, a wholly-owned subsidiary. bioAffinity Technologies is also expanding its platform to develop diagnostic tests for other lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).

Led by President and CEO Maria Zannes, bioAffinity Technologies has reported significant commercial progress. The company announced record revenue and unit sales for CyPath® Lung in 2025, with unit sales increasing by 99% year-over-year, and a 146% surge in Q1 2026 unit sales compared to the previous year. In March 2026, bioAffinity Technologies initiated a large-scale, longitudinal clinical study for CyPath® Lung. Additionally, the company launched a pilot study in April 2026 with Brooke Army Medical Center to evaluate new diagnostic tests for asthma and COPD, further solidifying its position in the expanding early-detection diagnostics market.